Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 05, 2015 9:58 AM ET

Life Sciences Tools and Services

Company Overview of MerLion Pharmaceuticals Pte. Ltd.

Company Overview

MerLion Pharmaceuticals Pte. Ltd., a drug discovery and development company, engages in the research and development of natural products. It operates through two business units, MerLion Research and MerLion Development. The MerLion Research unit is a contract services business, which provides access to natural product collections by offering sample/extract supply services, extract profiling and standardization, assay development, throughput screening, compound purification and structural identification, biocatalyst isolation, and strain improvement. The MerLion Development unit is progressing finafloxacin, a differentiated antibacterial candidate through phase II clinical trials, which is ta...

1 Science Park Road

05-01 The Capricorn

Singapore Science Park II

Singapore,  117528

Singapore

Founded in 2002

Phone:

65 6829 5600

Fax:

65 6829 5601

Key Executives for MerLion Pharmaceuticals Pte. Ltd.

Chief Executive Officer
Head of Research
Managing Director of MerLion Pharmaceuticals GmbH
Compensation as of Fiscal Year 2015.

MerLion Pharmaceuticals Pte. Ltd. Key Developments

MerLion Announces FDA Approval of Finafloxacin Otic Suspension

MerLion Pharmaceuticals announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as swimmer's ear, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections. MerLion retains the rights to intravenous and oral formulations of finafloxacin for all other indications and recently announced positive results from a phase 2 trial conducted in Europe treating around 200 patients hospitalized with complicated urinary tract infections. The results from this study demonstrated positive outcomes at all primary and all secondary endpoints; with patients treated once daily for five days with finafloxacin seeing higher, more rapid and sustained level of microbiological eradication and improved clinical outcomes compared to those treated with the current standard of care (ciprofloxacin taken twice daily for 10 days).

MERLION Signs Distribution Agreement with RoomMates

MERLION announced signing of a distribution agreement with RoomMates. Production is located in Pennsylvania, York, USA. Company offers a unique range of license decals and also a wide choice of original designs of various subjects.

MerLion Pharmaceuticals Pte. Ltd. Appoints David Dally as Chief Executive Officer

MerLion Pharmaceuticals Pte. Ltd. announced the appointment of Mr. David Dally as Chief Executive Officer. Mr. Dally has been Chief Financial Officer of MerLion since February 2007. He has over 20 year's financial and commercial experience in the bio-medical industry, including senior roles with KuDOS Pharmaceuticals Ltd. and at Amersham plc. David will focus on developing strategic opportunities with both the systemic and topical formulations available within MerLion’s finafloxacin program.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MerLion Pharmaceuticals Pte. Ltd., please visit www.merlionpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.